Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00977210
Recruitment Status : Completed
First Posted : September 15, 2009
Last Update Posted : October 31, 2011
Cancer Research UK
Information provided by (Responsible Party):
Mateon Therapeutics